Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Respiratory Microbiota | Research

The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota

Authors: Yu Jia, Tiantian He, Di Wu, Jiabing Tong, Jie Zhu, Zegeng Li, Jingcheng Dong

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Chronic obstructive pulmonary disease (COPD), a prevalent, progressive respiratory disease, has become the third leading cause of death globally. Increasing evidence suggests that intestinal and pulmonary microbiota dysbiosis is associated with COPD. Researchers have shown that T helper (Th) 17/regulatory T (Treg) imbalance is involved in COPD. Qibai Pingfei Capsule (QBPF) is a traditional Chinese medicine used to treat COPD clinically in China. However, the effects of QBPF intervention on the Th17/Treg balance and microbiota in the gut and lung are still poorly understood.

Methods

This study divided the rats into three groups (n = 8): control, model, and QBPF group. After establishing the model of COPD for four weeks and administering of QBPF for two weeks, Th17 cells, Treg cells, their associated cytokines, transcription factors, and intestinal and pulmonary microbiota of rats were analyzed. Furthermore, the correlations between intestinal and pulmonary microbiota and between bacterial genera and pulmonary function and immune function were measured.

Results

The results revealed that QBPF could improve pulmonary function and contribute to the new balance of Th17/Treg in COPD rats. Meanwhile, QBPF treatment could regulate the composition of intestinal and pulmonary microbiota and improve community structure in COPD rats, suppressing the relative abundance of Coprococcus_2, Prevotella_9, and Blautia in the gut and Mycoplasma in the lung, but accumulating the relative abundance of Prevotellaceae_UCG_003 in the gut and Rikenellaceae_RC9_gut_group in the lung. Additionally, gut–lung axis was confirmed by the significant correlations between the intestinal and pulmonary microbiota. Functional analysis of microbiota showed amino acid metabolism was altered in COPD rats in the gut and lung. Spearman correlation analysis further enriched the relationship between the microbiota in the gut and lung and pulmonary function and immune function in COPD model rats.

Conclusions

Our study indicated that the therapeutic effects of QBPF may be achieved by maintaining the immune cell balance and regulating the gut-lung axis microbiota, providing references to explore the potential biomarkers of COPD and the possible mechanism of QBPF to treat COPD.
Appendix
Available only for authorised users
Literature
1.
Wen F, Lei L. The current status of Chinese Clinicians’ cognition of chronic obstructive pulmonary disease and their coping strategies. Med J West China. 2021;33(1):1–3.
2.
Jiang M, Cai R, Wang J, Li Z, Xu D, Jing J, et al. ILC2 cells promote Th2 cell differentiation in AECOPD through activated Notch-GATA3 signaling pathway. Front Immunol. 2021;12: 685400.PubMedPubMedCentralCrossRef
3.
Zheng X, Zhang L, Chen J, Gu Y, Xu J, Ouyang Y. Dendritic cells and Th17/Treg ratio play critical roles in pathogenic process of chronic obstructive pulmonary disease. Biomed Pharmacother. 2018;108:1141–51.PubMedCrossRef
4.
Su YC, Jalalvand F, Thegerström J, Riesbeck K. The interplay between immune response and bacterial infection in COPD: focus upon non-typeable Haemophilus influenzae. Front Immunol. 2018;9:2530.PubMedPubMedCentralCrossRef
5.
Cervilha DAB, Ito JT, Lourenço JD, Olivo CR, Saraiva-Romanholo BM, Volpini RA, et al. The Th17/Treg cytokine imbalance in chronic obstructive pulmonary disease exacerbation in an animal model of cigarette smoke exposure and lipopolysaccharide challenge association. Sci Rep. 2019;9(1):1921.PubMedPubMedCentralCrossRef
6.
Segal JP, Mullish BH, Quraishi MN, Acharjee A, Williams HRT, Iqbal T, et al. The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease. Therap Adv Gastroenterol. 2019;12:1756284818822250.PubMedPubMedCentralCrossRef
7.
Parks DH, Rinke C, Chuvochina M, Chaumeil PA, Woodcroft BJ, Evans PN, et al. Recovery of nearly 8,000 metagenome-assembled genomes substantially expands the tree of life. Nat Microbiol. 2017;2(11):1533–42.PubMedCrossRef
8.
Shi CY, Yu CH, Yu WY, Ying HZ. Gut-lung microbiota in chronic pulmonary diseases: evolution, pathogenesis, and therapeutics. Can J Infect Dis Med Microbiol. 2021;2021:9278441.PubMedPubMedCentralCrossRef
9.
Stephens RW, Arhire L, Covasa M. Gut microbiota: from microorganisms to metabolic organ influencing obesity. Obesity (Silver Spring). 2018;26(5):801–9.CrossRef
10.
Lai HC, Lin TL, Chen TW, Kuo YL, Chang CJ, Wu TR, et al. Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide. Gut. 2022;71(2):309–21.PubMedCrossRef
11.
Li N, Dai Z, Wang Z, Deng Z, Zhang J, Pu J, et al. Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease. Respir Res. 2021;22(1):274.PubMedPubMedCentralCrossRef
12.
Adar SD, Huffnagle GB, Curtis JL. The respiratory microbiome: an underappreciated player in the human response to inhaled pollutants? Ann Epidemiol. 2016;26(5):355–9.PubMedPubMedCentralCrossRef
13.
Soret P, Vandenborght LE, Francis F, Coron N, Enaud R, Avalos M, et al. Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis. Sci Rep. 2020;10(1):3589.PubMedPubMedCentralCrossRef
14.
Kim KH, Kabir E, Kabir S. A review on the human health impact of airborne particulate matter. Environ Int. 2015;74:136–43.PubMedCrossRef
15.
Moffatt MF, Cookson WO. The lung microbiome in health and disease. Clin Med (Lond). 2017;17(6):525–9.CrossRef
16.
Faner R, Sibila O, Agustí A, Bernasconi E, Chalmers JD, Huffnagle GB, et al. The microbiome in respiratory medicine: current challenges and future perspectives. Eur Respir J. 2017;49(4):1602086.PubMedCrossRef
17.
D’Alessandro G, Antonangeli F, Marrocco F, Porzia A, Lauro C, Santoni A, et al. Gut microbiota alterations affect glioma growth and innate immune cells involved in tumor immunosurveillance in mice. Eur J Immunol. 2020;50(5):705–11.PubMedPubMedCentralCrossRef
18.
Garcia-Nuñez M, Marti S, Puig C, Perez-Brocal V, Millares L, Santos S, et al. Bronchial microbiome, PA biofilm-forming capacity and exacerbation in severe COPD patients colonized by P. aeruginosa. Future Microbiol. 2017;12:379–92.PubMedCrossRef
19.
Bernard-Raichon L, Colom A, Monard SC, Namouchi A, Cescato M, Garnier H, et al. A pulmonary Lactobacillus murinus strain induces Th17 and RORγt(+) regulatory T Cells and reduces lung inflammation in Tuberculosis. J Immunol. 2021;207(7):1857–70.PubMedCrossRef
20.
Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55–71.PubMedCrossRef
21.
Hu S, Fang X. Research progress between intestinal microbiota and immunity. Chin J Clin Healthcare. 2021;24(3):294–300.
22.
Xiao S, Zhang S. Recent advances in the relationship between intestinal flora and respiratory diseases. Chin General Pract. 2021;24(9):1165–72.
23.
Li N, Dai Z, Chen C, Zhang J, He F, Li J, et al. Establishment of COPD gut microbiota model with fecal microbiota transplantation and its evaluation. Chin J Respir Crit Care Med. 2021;20(7):465–71.
24.
25.
Zhang Y, Lu P, Qin H, Zhang Y, Sun X, Song X, et al. Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: rationale and therapeutic potential. Biomed Pharmacother. 2021;133: 111072.PubMedCrossRef
26.
Li J. International clinical practice guideline of Chinese medicine chronic obstructive pulmonary disease. World Chin Med. 2020;15(7):1084–92.
27.
Wang D, Xu B, Li Z, Peng B, Tong J, Yang C. Clinical observation on Qibai Pingfei Capsule in treating COPD of phlegm stasis obstructing the lung. Clin J Tradit Chin Med. 2012;24(04):301–2.
28.
Wang C, Li Z, Peng B, Tong J, Yang C. Effect of Qibai Pingfei Capsule on the SGRQ score of COPD patient. Chin Arch Tradit Chin Med. 2012;30(02):266–8.
29.
Tong J, Wang C, Peng B, Yang C, Li Z, Wang H. Therapeutic effect analysis of Qibai Pingfei Capsule on phlegm and blood stasis obstructing the lung type of COPD patient. Chin Arch Tradit Chin Med. 2012;30(01):44–5.
30.
Yin T, Li Z, Wang C, Lu L, Mao S, Zhang R, et al. Clinical research of Qibai Pingfei Capsule on “Lung Qi Deficiency and Missing” COPD pulmonary vasoconstriction regulation function. Clin J Tradit Chin Med. 2018;30(08):1459–64.
31.
Zhu Z, Shi M, Fang L, Zhu J, Li Z, Tong J. Effect of Qibai Pingfei Capsule on pulmonary inflammation and pulmonary function in rats with chronic obstructive pulmonary disease with syndrome of phlegm and blood stasis obstructing the lung. J Anhui Univ Chin Med. 2021;40(06):52–7.
32.
Fang L, Wang C, Wang J, Yin T, Tong J, Yang C, et al. Effect of Qi-Bai-Ping-Fei capsule on rock-1 and rock-2 expression in chronic obstructive pulmonary disease with phlegm and blood stasis syndrome rat. J Chengdu Univ Tradit Chin Med. 2015;38(03):13–16+47.
33.
Li Z, Wang C, Peng B, Tong J, Yang C. Effect of Qibai Pingfei Capsule on T—lymphocytes subsets of rats with phlegm and blood stasis syndrome of COPD. Chin Arch Tradit Chin Med. 2012;30(01):7–9.
34.
Jiang H, Li Z, Gao J, Meng M. Changes of CD4+CD25+Foxp3+ regulatory T cells in different stages of COPD and intervention of Qibai Pingfei Capsules. J Chin Med Mater. 2014;37(12):2244–7.
35.
Meng J, Cao Z, Li J. Effect of Qibai Pingfei Capsules combined with montelukast on expression of CD4+CD25+ regulatory T cells in patients with acute exacerbation of chronic obstructive pulmonary disease. J Emerg Tradit Chin Med. 2018;27(7):1253–5.
36.
Li Z, Wang C, Peng B, Tong J, Yang C, Zhang S. Establishment of rat model of chronic obstructive pulmonary disease with stagnated phlegm obstructing lung. Tianjin J Tradit Chin Med. 2010;27(1):43–5.
37.
38.
Daniel S, Phillippi D, Schneider LJ, Nguyen KN, Mirpuri J, Lund AK. Exposure to diesel exhaust particles results in altered lung microbial profiles, associated with increased reactive oxygen species/reactive nitrogen species and inflammation, in C57Bl/6 wildtype mice on a high-fat diet. Part Fibre Toxicol. 2021;18(1):3.PubMedPubMedCentralCrossRef
39.
Yang CY, Li SW, Chin CY, Hsu CW, Lee CC, Yeh YM, et al. Association of exacerbation phenotype with the sputum microbiome in chronic obstructive pulmonary disease patients during the clinically stable state. J Transl Med. 2021;19(1):121.PubMedPubMedCentralCrossRef
40.
Wu Y, Luo Z, Liu C. Variations in fecal microbial profiles of acute exacerbations and stable chronic obstructive pulmonary disease. Life Sci. 2021;265: 118738.PubMedCrossRef
41.
Pu Q, Lin P, Gao P, Wang Z, Guo K, Qin S, et al. Gut microbiota regulate gut-lung axis inflammatory responses by mediating ILC2 compartmental migration. J Immunol. 2021;207(1):257–67.PubMedCrossRef
42.
43.
Zhao L, Yang K, Li B, Wang Z, Chen X. Expression of CCR6-CCL20 and Th17 in peripheral blood of patients with chronic periodontitis. Beijing J Stomatol. 2020;28(5):262–5.
44.
Li W, Song Y, Ye A, An Y, Luo S, Liu S, et al. Effect of chemokine CCL20 and CCL22 combined with skin antigen-induced Treg on survival time of grafted skin. Chin J Immunol. 2016;32(9):1315–8.
45.
Gu Y, Fu D, Rao X, Ouyang Y. The changes of CCL20 and its receptor CCR6 in COPD airway and peripheral blood and the therapeutic effect of CCL20 antibodies. J Zunyi Med Univ. 2016;39(3):266–9.
46.
Elson CO, Alexander KL. Host-microbiota interactions in the intestine. Dig Dis. 2015;33(2):131–6.PubMedCrossRef
47.
Skelly AN, Sato Y, Kearney S, Honda K. Mining the microbiota for microbial and metabolite-based immunotherapies. Nat Rev Immunol. 2019;19(5):305–23.PubMedCrossRef
48.
Kehrmann J, Effenberg L, Wilk C, Schoemer D, Ngo Thi Phuong N, Adamczyk A, et al. Depletion of Foxp3(+) regulatory T cells is accompanied by an increase in the relative abundance of Firmicutes in the murine gut microbiome. Immunology. 2020;159(3):344–53.PubMedCrossRef
49.
Liu Q, Tian X, Maruyama D, Arjomandi M, Prakash A. Lung immune tone via gut-lung axis: gut-derived LPS and short-chain fatty acids’ immunometabolic regulation of lung IL-1β, FFAR2, and FFAR3 expression. Am J Physiol Lung Cell Mol Physiol. 2021;321(1):165-l78.CrossRef
50.
Ramírez-Labrada AG, Isla D, Artal A, Arias M, Rezusta A, Pardo J, et al. The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy. Trends Cancer. 2020;6(2):86–97.PubMedCrossRef
51.
Dickson RP, Erb-Downward JR, Falkowski NR, Hunter EM, Ashley SL, Huffnagle GB. The lung microbiota of healthy mice are highly variable, cluster by environment, and reflect variation in baseline lung innate immunity. Am J Respir Crit Care Med. 2018;198(4):497–508.PubMedPubMedCentralCrossRef
52.
Bell KJ, Saad S, Tillett BJ, et al. Metabolite-based dietary supplementation in human type 1 diabetes is associated with microbiota and immune modulation. Microbiome. 2022;10:9.PubMedPubMedCentralCrossRef
53.
Molyneaux PL, Mallia P, Cox MJ, Footitt J, Willis-Owen SA, Homola D, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(10):1224–31.PubMedPubMedCentralCrossRef
54.
Mo F, Ma S, Li H, Zhao D, Wang L, Ni J, et al. Discussion on the origin and connotation of the “lung and large intestine being interior exteriorly related” based on TCM classics. Glob Tradit Chin Med. 2015;8(2):165–8.
55.
Yang C, Bai J, Zang D, Xu J. A new approach to the treatment of respiratory infection with the spleen-strengthening formula based on pulmonary intestinal microecology. World Chin Med. 2021;16(20):3100–4.
56.
Raftery AL, Tsantikos E, Harris NL, Hibbs ML. Links between inflammatory bowel disease and chronic obstructive pulmonary disease. Front Immunol. 2020;11:2144.PubMedPubMedCentralCrossRef
57.
58.
Lan H, Gui Z, Zeng Z, Li D, Qian B, Qin LY, et al. Oral administration of Lactobacillus plantarum CQPC11 attenuated the airway inflammation in an ovalbumin (OVA)-induced Balb/c mouse model of asthma. J Food Biochem. 2022;46(2): e14036.PubMed
59.
Nakayama Y, Moriya T, Sakai F, Ikeda N, Shiozaki T, Hosoya T, et al. Oral administration of Lactobacillus gasseri SBT2055 is effective for preventing influenza in mice. Sci Rep. 2014;4:4638.PubMedPubMedCentralCrossRef
60.
Yamane T, Sakamoto T, Nakagaki T, Nakano Y. Lactic acid bacteria from kefir increase cytotoxicity of natural killer cells to tumor cells. Foods. 2018;7(4):48.PubMedCentralCrossRef
61.
Dorey RB, Theodosiou AA, Read RC, Jones CE. The nonpathogenic commensal Neisseria: friends and foes in infectious disease. Curr Opin Infect Dis. 2019;32(5):490–6.PubMedCrossRef
62.
Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M. The controversial role of human gut lachnospiraceae. Microorganisms. 2020;8(4):573.PubMedCentralCrossRef
63.
Qian L, Lu L, Huang L, Wen Q, Xie J, Jin W, et al. The effect of neonatal maternal separation on short-chain fatty acids and airway inflammation in adult asthma mice. Allergol Immunopathol (Madr). 2019;47(1):2–11.CrossRef
64.
Videvall E, Song SJ, Bensch HM, Strandh M, Engelbrecht A, Serfontein N, et al. Early-life gut dysbiosis linked to juvenile mortality in ostriches. Microbiome. 2020;8(1):147.PubMedPubMedCentralCrossRef
65.
Skennerton CT, Haroon MF, Briegel A, Shi J, Jensen GJ, Tyson GW, et al. Phylogenomic analysis of Candidatus “Izimaplasma” species: free-living representatives from a Tenericutes clade found in methane seeps. Isme J. 2016;10(11):2679–92.PubMedPubMedCentralCrossRef
66.
Ley RE. Gut microbiota in 2015: prevotella in the gut: choose carefully. Nat Rev Gastroenterol Hepatol. 2016;13(2):69–70.PubMedCrossRef
67.
68.
Sultan M, Wilson K, Abdulla OA, Busbee PB, Hall A, Carter T, et al. Endocannabinoid anandamide attenuates acute respiratory distress syndrome through modulation of microbiome in the gut-lung axis. Cells. 2021;10(12):3305.PubMedPubMedCentralCrossRef
69.
Engelen M, Jonker R, Thaden JJ, Ten Have GAM, Jeon MS, Dasarathy S, et al. Comprehensive metabolic flux analysis to explain skeletal muscle weakness in COPD. Clin Nutr. 2020;39(10):3056–65.PubMedPubMedCentralCrossRef
70.
Jonker R, Deutz NE, Erbland ML, Anderson PJ, Engelen MP. Alterations in whole-body arginine metabolism in chronic obstructive pulmonary disease. Am J Clin Nutr. 2016;103(6):1458–64.PubMedPubMedCentralCrossRef
71.
Wang CH, Cheng ML, Liu MH. Amino acid-based metabolic panel provides robust prognostic value additive to B-natriuretic peptide and traditional risk factors in heart failure. Dis Markers. 2018;2018:3784589.PubMedPubMedCentral
72.
Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, Tal-Singer R, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst. 2012;8(12):3125–33.PubMedCrossRef
73.
Kang YP, Lee SB, Lee JM, Kim HM, Hong JY, Lee WJ, et al. Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis. J Proteome Res. 2016;15(5):1717–24.PubMedCrossRef
74.
Aida Y, Shibata Y, Osaka D, Abe S, Inoue S, Fukuzaki K, et al. The relationship between serum uric acid and spirometric values in participants in a health check: the Takahata study. Int J Med Sci. 2011;8(6):470–8.PubMedPubMedCentralCrossRef
75.
76.
Qu Z, Zhang L, Hou R, Ma X, Yu J, Zhang W, et al. Exposure to a mixture of cigarette smoke carcinogens disturbs gut microbiota and influences metabolic homeostasis in A/J mice. Chem Biol Interact. 2021;344: 109496.PubMedCrossRef
77.
Zhang M, Zhou H, Xu S, Liu D, Cheng Y, Gao B, et al. The gut microbiome can be used to predict the gastrointestinal response and efficacy of lung cancer patients undergoing chemotherapy. Ann Palliat Med. 2020;9(6):4211–27.PubMedCrossRef
78.
Chiu YC, Lee SW, Liu CW, Lan TY, Wu LS. Relationship between gut microbiota and lung function decline in patients with chronic obstructive pulmonary disease: a 1-year follow-up study. Respir Res. 2022;23(1):10.PubMedPubMedCentralCrossRef
79.
Wang Y, Li N, Li Q, Liu Z, Li Y, Kong J, et al. Xuanbai Chengqi decoction ameliorates pulmonary inflammation via reshaping gut microbiota and rectifying Th17/Treg imbalance in a murine model of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:3317–35.PubMedPubMedCentralCrossRef
80.
Gómez Rufo D, García Sánchez E, García Sánchez JE, García MM. Clinical implications of the genus Mycoplasma. Rev Esp Quimioter. 2021;34(3):169–84.PubMedCrossRef
81.
Barge L, Pahn G, Weber N. Transient immune-mediated agranulocytosis following Mycoplasma pneumoniae infection. BMJ Case Rep. 2018;2018:bcr2018.
82.
Tavella T, Rampelli S, Guidarelli G, Bazzocchi A, Gasperini C, Pujos-Guillot E, et al. Elevated gut microbiome abundance of Christensenellaceae, Porphyromonadaceae and Rikenellaceae is associated with reduced visceral adipose tissue and healthier metabolic profile in Italian elderly. Gut Microbes. 2021;13(1):1–19.PubMedCrossRef
83.
Zhou L, Ni Z, Yu J, Cheng W, Cai Z, Yu C. Correlation between fecal metabolomics and gut microbiota in obesity and polycystic ovary syndrome. Front Endocrinol (Lausanne). 2020;11:628.CrossRef
84.
85.
Benítez-Páez A, Gómez Del Pugar EM, López-Almela I, Moya-Pérez Á, Codoñer-Franch P, Sanz Y. Depletion of Blautia species in the microbiota of obese Children relates to intestinal inflammation and metabolic phenotype worsening. mSystems. 2020;5(2):e008574-19.CrossRef
86.
Wang J, Wu Q, Ding L, Song S, Li Y, Shi L, et al. Therapeutic effects and molecular mechanisms of bioactive compounds against respiratory diseases: traditional Chinese medicine theory and high-frequency use. Front Pharmacol. 2021;12: 734450.PubMedPubMedCentralCrossRef
87.
Zhang J, Wu C, Gao L, Du G, Qin X. Astragaloside IV derived from Astragalus membranaceus: a research review on the pharmacological effects. Adv Pharmacol. 2020;87:89–112.PubMedCrossRef
88.
Guan S, Yu P, Cao J, Xi X, Zhang Q, Zhu C, et al. Ginsenoside Rg1 protects against cigarette smoke-induced airway remodeling by suppressing the TGF-β1/Smad3 signaling pathway. Am J Transl Res. 2020;12(2):493–506.PubMedPubMedCentral
89.
Guan X, Yuan Y, Wang G, Zheng R, Zhang J, Dong B, et al. Ginsenoside Rg3 ameliorates acute exacerbation of COPD by suppressing neutrophil migration. Int Immunopharmacol. 2020;83: 106449.PubMedCrossRef
90.
Ji NF, Xie YC, Zhang MS, Zhao X, Cheng H, Wang H, et al. Ligustrazine corrects Th1/Th2 and Treg/Th17 imbalance in a mouse asthma model. Int Immunopharmacol. 2014;21(1):76–81.PubMedCrossRef
91.
Wu ZQ, Li K, Ma JK, Huang Q, Tian X, Li ZJ. Antioxidant activity of organic sulfides from fresh Allium macrostemon Bunge and their protective effects against oxidative stress in Caenorhabditis elegans. J Food Biochem. 2020;44(11): e13447.PubMed
92.
Xu M, Zhang J, Qiu J, Chen H. Research progress on processing methods and pharmacological effects of Tinglizi (Descurainiae Semen Lepidii Semen). Guid J Tradit Chin Med Pharm. 2021;27(10):132–7.
93.
Zhang D, Hu S, Li W, Ao R, Wu Z, Zhang Z, et al. Schisandra A ameliorates cigarette smoke extract and lipopolysaccharide-induced oxidative stress in lung epithelial cells. J Thorac Dis. 2020;12(3):394–402.PubMedPubMedCentralCrossRef
94.
Chen H, Zhang W, Guo J, Song Q, Wang W. Effects of earthworm extract on inflammatory cytokines in mice with paraquat induced pulmonary fibrosis. Inf Tradit Chin Med. 2020;37(4):19–22.
95.
Jiao J, Qi T, Tie-Jie W, et al. The therapeutic effect of Xuanbai Chengqi Decoction on chronic obstructive pulmonary disease with excessive heat in the lung and fu-organs based on gut and lung microbiota as well as metabolic profiles. J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1198: 123250.PubMedCrossRef
96.
Qian G, Can Ni, Linjing Li, et al. Integrated traditional Chinese medicine improves functional outcome in acute Ischemic stroke: from clinic to mechanism exploration with gut microbiota. Front Cell Infect Microbiol. 2022;12: 827129.CrossRef
97.
Tong X, Xu J, Lian F, Yu X, Zhao Y, Xu L, et al. Structural alteration of gut microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal formula: a multicenter, randomized open label clinical trial. MBio. 2018;9(3):e02392-17.PubMedPubMedCentralCrossRef
Metadata
Title
The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota
Authors
Yu Jia
Tiantian He
Di Wu
Jiabing Tong
Jie Zhu
Zegeng Li
Jingcheng Dong
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03481-w

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Research

Gene signatures, immune infiltration, and drug sensitivity based on a comprehensive analysis of m6a RNA methylation regulators in cervical cancer

Research

Ligand-activated PPARδ expression promotes hepatocellular carcinoma progression by regulating the PI3K-AKT signaling pathway

Review

Untargeted metabolomics analysis of esophageal squamous cell cancer progression

Research

Estrogen antagonizes ASIC1a-induced chondrocyte mitochondrial stress in rheumatoid arthritis

Research

From Bowen disease to cutaneous squamous cell carcinoma: eight markers were verified from transcriptomic and proteomic analyses

Research

Zishen pingchan granules combined with pramipexole in the improvement of depressive symptoms in Parkinson's disease: a prospective, multicenter, randomized, double-blind, controlled clinical study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits